Seres therapeutics, inc. (MCRB)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15
Cash flows from operating activities:
Net loss

-65,827

-70,279

-72,788

-78,328

-95,356

-98,942

-106,608

-91,594

-91,825

-89,380

-85,703

-97,454

-97,349

-91,579

-85,937

-81,871

-66,513

-54,780

0

0

0

Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense

8,238

8,344

9,953

12,233

14,470

16,641

17,099

17,151

17,319

17,362

17,142

17,017

17,232

16,857

15,652

13,915

12,271

9,694

0

0

0

Depreciation and amortization expense

7,399

7,603

7,796

7,894

7,927

7,862

7,772

7,664

7,470

7,259

7,050

6,435

5,549

4,205

2,845

1,776

1,022

728

0

0

0

Non-cash operating lease cost

2,228

2,227

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accretion of discount on investments

0

-

-

-

-

214

249

232

207

216

0

0

0

-

-

-

-

-

-

-

-

Loss from revaluation of preferred stock warrant liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

7

0

0

0

Non-cash interest expense

0

-

-

-

-

-

-

-

-

3

0

0

0

-

100

227

391

367

0

0

0

Changes in operating assets and liabilities:
Prepaid expenses and other current assets

-4,103

-3,257

-2,177

-5

3,534

2,056

1,210

632

-928

-31

291

-408

1,620

2,598

2,035

2,959

2,800

2,470

0

0

0

Accounts receivable

-4,645

1,785

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred revenue

-23,946

-17,520

12,095

9,711

16,860

13,476

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Deferred revenue

-

-

-

-

-

-

-

-

-

-

0

0

-11,491

-

0

0

0

-

-

-

-

Accounts payable

1,604

-1,460

-2,316

-461

-1,401

-353

1,752

1,258

-366

-856

995

-465

334

3,581

2,234

3,218

4,202

2,682

0

0

0

Operating lease liabilities

-4,253

-4,211

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accrued expenses and other liabilities

-

-

-

-

-

-

-

-

2,509

2,162

-2,904

2,459

4,698

5,027

9,070

4,778

2,828

2,928

0

0

0

Accrued expenses and other current and long-term liabilities

0

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash (used in) operating activities

-68,378

-76,520

-49,807

-54,598

-68,484

-62,854

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Cash flows from investing activities:
Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-

-83,143

-

53,157

53,245

68,911

-40,844

0

0

0

Purchases of property and equipment

767

1,002

576

929

1,290

1,937

2,818

2,804

3,382

4,676

9,678

15,073

20,339

21,492

17,041

12,659

7,548

4,362

0

0

0

Purchases of investments

0

-

-

-

-

21,832

44,038

69,595

80,691

97,934

120,594

127,855

267,806

290,594

316,389

410,045

253,807

267,761

0

0

0

Sales and maturities of investments

0

-

-

-

-

136,087

151,074

172,000

164,818

158,312

196,389

198,966

217,820

246,494

0

0

0

-

-

-

-

Net cash (used in) provided by investing activities

-20,775

-30,518

-17,775

37,287

73,978

112,318

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Cash flows from financing activities:
Proceeds from exercise of stock options

85

145

156

171

235

147

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from issuance of common stock and restricted common stock

143

176

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from at the market equity offering, net of commissions

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Changes in restricted cash

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

Net cash provided by investing activities

-

-

-

-

-

-

-

-

-

-

-

-

-70,185

-

-69,388

-171,105

-59,941

-137,133

0

0

0

Proceeds from issuance of convertible preferred stock, net of issuance costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-24

0

0

0

Proceeds from exercise of stock options and common stock warrants

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

330

262

0

0

0

Payments for repurchase of common stock for employee tax withholdings

-

-

-

-

-

197

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Issuance of common stock under ESPP plan

338

296

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by financing activities

90,296

86,231

61,166

61,582

913

268

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Net increase (decrease) in cash and cash equivalents

1,143

-20,807

-6,416

44,271

6,407

49,732

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Repayment of notes payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2,600

0

0

0

Payments of initial public offering costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2,928

0

0

0

Net cash (used in) provided by financing activities

-

-

-

-

-

-

-

-

-

-

-

-

2,000

-

2,140

141,346

139,213

137,725

0

0

0

Net increase (decrease) in cash, cash equivalents and restricted cash

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

Net increase (decrease) in cash and cash equivalents

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-14,091

23,486

148,183

-40,252

0

0

0

Supplemental disclosure of cash flow information:
Cash paid for interest

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cash paid for interest

-

-

-

-

-

-

-

-

-

-

-

-

-

-

110

196

133

163

0

0

0

Supplemental disclosure of non-cash investing and financing activities:
Unsettled issuance of common stock from the at the market offering

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred offering costs included in accounts payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Property and equipment purchases included in accounts payable and accrued expenses

61

62

-31

155

-102

157

666

827

921

877

-2,381

-3,109

-1,396

1,650

6,789

7,134

6,320

2,953

0

0

0